Deconstruction and in vivo functionalization of the ceRNA cancer network (PQ-11)

ceRNA癌症网络的解构和体内功能化(PQ-11)

基本信息

项目摘要

DESCRIPTION (provided by applicant): We have recently discovered a novel means of gene regulation whereby both protein-coding and non-coding RNAs are able to cross-talk through a new RNA language. In this new regulatory dimension, both protein-coding and non-coding RNAs (e.g. pseudogenes) can communicate with each other by competing for common microRNAs, hence acting as "competing endogenous RNAs" or ceRNAs. We have described several ceRNAs that regulate the tumor suppressor PTEN, thereby ascribing tumor suppressive functions to numerous cancer-unrelated mRNAs and non-coding RNAs. Moreover, we have developed a methodology to computationally predict ceRNAs for cancer-associated genes based upon the identity of their microRNA response elements (MREs), which are the foundation of this new language. This allows for the prediction and identification of novel putative tumor suppressors and oncogenes, and, critically, for the functionalization of the entire cancer-relevant transcriptome. We therefore propose to further characterize oncogenic and tumor suppressive ceRNA networks in vitro. Additionally, to explore the function of ceRNAs in basic biology in vivo, we have created a series of mouse models that express pseudogenes or 3'UTRs or lack established PTEN ceRNAs in an inducible manner. We will cross these mice to existing mouse models of cancer to characterize the contribution of ceRNAs to the malignant phenotype in vivo. We propose to address these outstanding questions pertaining to this new transformative biological dimension with the following specific aims: (1) to identify and functionally characteriz novel tumor suppressive PTEN ceRNAs as well as to analyze mouse models lacking bona fide PTEN ceRNAs such as ZEB2 and VHL; (2) to explore the effect of PTEN 3'UTR overexpression on the malignant phenotype elicited by either PTEN heterozygosity or overexpression of the PTEN targeting miR106b~25 cluster; (3) to analyze the ceRNA activity of the pseudogene BRAFps towards its ancestral gene, the proto-oncogene BRAF, in vitro and in vivo and its contribution to cancer development. We strongly believe that our application is both highly innovative and timely, with the potential to significantly further our understanding of this novel process of gene regulation in cancer genetics and biology.
描述(由申请人提供):我们最近发现了一种新的基因调控手段,由此蛋白质编码和非编码RNA都能够通过新的RNA语言进行交互。在这种新的调控维度中,蛋白质编码和非编码RNA(例如假基因)可以通过竞争共同的microRNA而彼此通信,因此充当“竞争性内源RNA”或ceRNA。我们已经描述了几种调节肿瘤抑制因子PTEN的ceRNA,从而将肿瘤抑制功能归因于许多与癌症无关的mRNA和非编码RNA。此外,我们还开发了一种方法,根据其microRNA响应元件(MRE)的身份来计算预测癌症相关基因的ceRNA,这是这种新语言的基础。这允许预测和鉴定新的推定的肿瘤抑制因子和癌基因,并且,关键地,允许整个癌症相关基因的功能化。 转录组因此,我们建议在体外进一步表征致癌和肿瘤抑制ceRNA网络。此外,为了探索ceRNA在体内基础生物学中的功能,我们已经建立了一系列以诱导方式表达假基因或3 'UTR或缺乏已建立的PTEN ceRNA的小鼠模型。我们将这些小鼠与现有的小鼠癌症模型杂交,以表征ceRNA对体内恶性表型的贡献。我们提出了解决这些悬而未决的问题与这个新的变革性的生物学维度与以下具体目标:(1)鉴定和功能表征新的肿瘤抑制性PTEN ceRNA以及分析缺乏真正的PTEN ceRNA的小鼠模型,如ZEB 2和VHL;(2)探讨PTEN 3 'UTR过表达对PTEN杂合性或靶向miR 106 b ~(-1)的PTEN过表达诱导的恶性表型的影响。25簇;(3)分析假基因BRAFps在体外和体内对其祖先基因原癌基因BRAF的ceRNA活性及其对癌症发展的贡献。我们坚信,我们的应用是高度创新和及时的,有可能大大加深我们对癌症遗传学和生物学中基因调控这一新过程的理解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PIER PAOLO PANDOLFI其他文献

PIER PAOLO PANDOLFI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PIER PAOLO PANDOLFI', 18)}}的其他基金

NPM1 regulation of 2'-O-methylation in hematopoiesis and bone marrow failure disorder
NPM1 对造血和骨髓衰竭疾病中 2-O-甲基化的调节
  • 批准号:
    9424098
  • 财政年份:
    2017
  • 资助金额:
    $ 33.94万
  • 项目类别:
Dissecting the Therapeutic Role of Pt3K aod AR Pathway Inhibition In Prostate Cancer
剖析 Pt3K aod AR 通路抑制在前列腺癌中的治疗作用
  • 批准号:
    8730086
  • 财政年份:
    2014
  • 资助金额:
    $ 33.94万
  • 项目类别:
Deconstruction and in vivo functionalization of the ceRNA cancer network (PQ-11)
ceRNA癌症网络的解构和体内功能化(PQ-11)
  • 批准号:
    8374041
  • 财政年份:
    2012
  • 资助金额:
    $ 33.94万
  • 项目类别:
Deconstruction and in vivo functionalization of the ceRNA cancer network (PQ-11)
ceRNA癌症网络的解构和体内功能化(PQ-11)
  • 批准号:
    8701257
  • 财政年份:
    2012
  • 资助金额:
    $ 33.94万
  • 项目类别:
Identification and Characterization of Cell Autonomous Determinants that Promote
促进细胞自主决定因素的鉴定和表征
  • 批准号:
    8555536
  • 财政年份:
    2011
  • 资助金额:
    $ 33.94万
  • 项目类别:
A metabolic role for PML in tumor suppression
PML 在肿瘤抑制中的代谢作用
  • 批准号:
    8433446
  • 财政年份:
    2010
  • 资助金额:
    $ 33.94万
  • 项目类别:
Role of DOK family proteins in lung tumor suppression
DOK家族蛋白在抑制肺肿瘤中的作用
  • 批准号:
    8620547
  • 财政年份:
    2010
  • 资助金额:
    $ 33.94万
  • 项目类别:
A metabolic role for PML in tumor suppression
PML 在肿瘤抑制中的代谢作用
  • 批准号:
    8611710
  • 财政年份:
    2010
  • 资助金额:
    $ 33.94万
  • 项目类别:
Role of DOK family proteins in lung tumor suppression
DOK家族蛋白在抑制肺肿瘤中的作用
  • 批准号:
    8242824
  • 财政年份:
    2010
  • 资助金额:
    $ 33.94万
  • 项目类别:
Targeting PML for leukemia therapy.
针对 PML 进行白血病治疗。
  • 批准号:
    7768030
  • 财政年份:
    2010
  • 资助金额:
    $ 33.94万
  • 项目类别:

相似海外基金

Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
  • 批准号:
    573541-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 33.94万
  • 项目类别:
    University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
  • 批准号:
    2744317
  • 财政年份:
    2022
  • 资助金额:
    $ 33.94万
  • 项目类别:
    Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
  • 批准号:
    MR/V010948/1
  • 财政年份:
    2021
  • 资助金额:
    $ 33.94万
  • 项目类别:
    Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
  • 批准号:
    10019570
  • 财政年份:
    2019
  • 资助金额:
    $ 33.94万
  • 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
  • 批准号:
    10223370
  • 财政年份:
    2019
  • 资助金额:
    $ 33.94万
  • 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
  • 批准号:
    10455108
  • 财政年份:
    2019
  • 资助金额:
    $ 33.94万
  • 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
  • 批准号:
    255762
  • 财政年份:
    2012
  • 资助金额:
    $ 33.94万
  • 项目类别:
    Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
  • 批准号:
    20790351
  • 财政年份:
    2008
  • 资助金额:
    $ 33.94万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
  • 批准号:
    19370021
  • 财政年份:
    2007
  • 资助金额:
    $ 33.94万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
  • 批准号:
    7131841
  • 财政年份:
    2006
  • 资助金额:
    $ 33.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了